Zenas BioPharma Inc. (NASDAQ:ZBIO)
Old Forum Content for ZBIO
Make a Forum Post Become a member to view recent forum posts. Already a member? Sign in here.
- woodman: $Biotech holding up well. I have several, and only $NKTR is giving me a caution sign. Others (in no particular order) are doing fine: $CELC $INSM $BBIO $ZBIO $GPCR $VKTX
- woodman: Current Biotech positions: $VKTX $GPCR $INSM $NKTR $BBIO $ZBIO $CELC $LABU. I've been building these up over the last couple months, but not reporting on them because biotech is a minefield and I was reluctant to mention them frequently. But the path has been undeniable for so many bios. I'm not smoking hopium on these, though. I'm in for the charts with a dash of good stories that could keep them going. It is vital, however, to know their catalyst dates or you could get T-boned without seeing it coming. In fact, I am probably in unsafe harbor having this many at once; I need to re-review each of them for the reason stated.
- kenb: @woodman $VKTX $GPCR $INSM $NKTR $BBIO $ZBIO $CELC $LABU and adding $ARDX to the list. I'm still holding a large chunk and it's moving up as well from the depths finally.
- woodman: @kenb $VKTX $GPCR $INSM $NKTR $BBIO $ZBIO $CELC $LABU $ARDX - I like ARDX as a biotech with a commercialized product serving two indications (IBS with constipation and hyperphosphatemia). My short-intermediate concern is over its appeal on the Xphoza ...
- joelsg1: @woodman $VKTX $GPCR $INSM $NKTR $BBIO $ZBIO $CELC $LABU Tailwind for group is rapid changes at FDA, particulary the Center for Drug Development and Research, to emphasize faster and less rigorous drug approvals.
- woodman: @joelsg1 $VKTX $GPCR $INSM $NKTR $BBIO $ZBIO $CELC $LABU - Yep, but who the hell knows what's really going on over at FDA and CEDR (Center for Drug Evaluation and Research) now. Cluster F with all the changes in personnel, string-pulling, and whatever guiding priniples there now. Here's some info on the brand new head of CEDR - https://www.fiercepharma.com/pharma/fda-names-longtime-oncology-chief-richard-pazdur-its-new-cder-director
- joelsg1: @woodman $VKTX $GPCR $INSM $NKTR $BBIO $ZBIO $CELC $LABU Seems it's pay-to-play over there, in keeping with Administration priorities.
- woodman: @joelsg1 $VKTX $GPCR $INSM $NKTR $BBIO $ZBIO $CELC $LABU - And science has taken a back seat.
- woodman: $ZBIO has been strong.
- DavidK: @woodman $ZBIO $BCRX- any thoughts on this stock . I used to follow it and saw where earnings were ok revenue beat . Analyst seem Patrice with a $19 PT . Been beat up .
- woodman: @DavidK $ZBIO $BCRX - I haven't looked at it in years. I'm no help.
- DavidK: @woodman $ZBIO correction on $BCRX. Slight miss on revenue . Turned a small profit. .stock been beaten up but has had positive analyst sentiment.
- DavidK: @woodman $ZBIO $BCRX ok thanks
- woodman: $ZBIO - decent ascender.
- Onthemark: Started some $FIG, $ZBIO, $GTBP, $TEM, and $MRVL. Added to $ACHR, $JOBY and $CIFR. Big day for $SPRY with a higher high after the huge prior downtrend. Received some European patents. Also holding rival $AQST. There's room for both products in this world.
- issues: @issues $USLV Some of the bear efts are $TZA $FAZ $ERY $SPXU $SDS $SOXS $LABD $BIS $ $ZBIO
- woodman: #Biotech is a disaster. I bought $ZBIO yesterday and uncharacteristically held it over night. Still holding it. Look at $LABD too.
- HooDat06: @woodman $ZBIO $LABD #Biotech $GILD still holding on. Could be a good sign, right?
- woodman: @HooDat06 $ZBIO $LABD $GILD #Biotech - Don't know about GILD. Maybe it is okay. But I'm taking my cues more from the broader sector - i.e. mostly from $IBB and $XBI. But there will always be some that buck the trend, so maybe $GILD will be one of t ...
- woodman: @Bridget $BIS I was just looking at $ZBIO and $LABD
| Stock Price | $26.50 |
| Change | 1.49% |
| Volume | 927,174 |
Zenas is a clinical-stage global biopharmaceutical company committed to becoming a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases. Our core business strategy combines our experienced leadership team with a disciplined product candidate acquisition approach to identify, acquire and develop product candidates globally that we believe can provide superior clinical benefits to patients living with autoimmune diseases. Zenas is advancing two late-stage, potential franchise molecules, obexelimab and orelabrutinib. Obexelimab, Zenas' lead product candidate, is a bifunctional monoclonal antibody designed to bind both CD19 and Fc¿RIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.
Request Video of ZBIOAlready a member? Sign in here.
Past Month
Leading Peers
-
$9.58 177.11%
-
$31.60 48.17%
-
$27.00 27.00%
Past Month
Lagging Peers
-
$8.91 -124.71%
-
$12.56 -37.15%
-
$84.11 -21.90%
Dan Fitzpatrick
Stock Market Mentor gives you EVERYTHING you need to succeed in the market; all in one place. How easy is that? Dan Fitzpatrick and his elite community of traders share trading ideas, strategies and much more. Dan Fitzpatrick--a world class Technical Analyst, trading coach and regular CNBC contributor--gives you access to all of this with a 30 day trial membership for just $7.77. Get started TODAY and start trading better TOMORROW with the following premium content:
- Nightly video Strategy Sessions with a game plan for tomorrow
- Got a stock you want Dan to look at? Just ask.
- Patent pending video alerts instantly delivered to you when one of Dan’s trading signals is triggered. This is not your typical price alert. This is a short video explaining the action you need to take to make money. No more “Woulda, coulda, shoulda”
- Access to over 90,400 stock analysis videos
- Access an ever expanding library (90,400) of educational videos that will save you time and make you money
Join a team of friends and traders that have one thing in common; a burning desire to succeed.
Become a Member Today!
Gain immediate access to all our exclusive articles, features, how-to's, discussion group and much more...
Satisfaction Guaranteed!
Your Stock Market Mentor membership comes with a 30 day, no questions asked, 100% money back guarantee!